RPG Life Sciences: Pharma's Rising Star!
RPG Life Sciences, a smallcap pharma company, has been upgraded to 'Buy' by MarketsMojo due to its high management efficiency, low debt to equity ratio, and positive financial results. The stock is currently in a Mildly Bullish range with a Very Attractive valuation and has consistently outperformed the BSE 500 index. Institutional investors have also shown increased interest in the company, making it a stock to watch in the pharma industry.
RPG Life Sciences, a smallcap pharma company, has recently been upgraded from 'Strong Buy' to 'Buy' by MarketsMOJO. The company has shown high management efficiency with a ROE of 20.08% and has a low Debt to Equity ratio of 0.01 times on average.In addition, RPG Life Sciences has reported positive results in September 2023, with its OPERATING CF (Y) reaching a high of Rs 90.81 Cr and NET SALES (Q) at Rs 153.58 Cr. The company's PBDIT (Q) also showed a significant increase at Rs 37.29 Cr.
Technically, the stock is currently in a Mildly Bullish range and both its MACD and KST technical factors are Bullish. With a ROE of 23.1 and a 6.8 Price to Book Value, the stock is deemed to have a Very Attractive valuation, although it is trading at a premium compared to its average historical valuations.
Over the past year, the stock has generated a return of 52.08%, while its profits have increased by 28.3%. The PEG ratio of the company stands at 1, indicating a balanced growth potential. Furthermore, RPG Life Sciences has seen an increase in participation by institutional investors, with a 1.43% increase in their stake over the previous quarter. These investors have better resources and capabilities to analyze the fundamentals of companies compared to most retail investors.
The company has consistently delivered strong returns over the last 3 years, outperforming the BSE 500 index in each of the last 3 annual periods. With its positive financial performance and increasing interest from institutional investors, RPG Life Sciences is a stock to watch out for in the pharma industry.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
